Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

L5025

Sigma-Aldrich

Leflunomide

Immunosuppressant

Sinonimo/i:

5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C12H9F3N2O2
Numero CAS:
75706-12-6
Peso molecolare:
270.21
Numero MDL:
MFCD00867593
Codice UNSPSC:
12352202
ID PubChem:
24278516
NACRES:
NA.77

Livello qualitativo

200

Saggio

≥98% (TLC)

Forma fisica

powder

Punto di fusione

166.5 °C

Solubilità

methanol: 19.60-20.40 mg/mL, clear, colorless to faintly yellow

Modalità d’azione

enzyme | inhibits

Temperatura di conservazione

2-8°C

Stringa SMILE

Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F

InChI

1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)
VHOGYURTWQBHIL-UHFFFAOYSA-N

Informazioni sul gene

human ... DHODH(1723)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

By virtue of its immunosuppressant effects, leflunomide has found use in organ transplantation and treatment of rheumatoid arthritis and other autoimmune diseases.

Azioni biochim/fisiol

Immunosuppressive; inhibits T and B cell proliferation. Activity is attributed mainly to its metabolite, a malononitrile derivative, which is believed to inhibit dihydroorotate dehydrogenase (in the de novo pyrimidine synthesis pathway) as well as several protein tyrosine kinases.

Pittogrammi

Skull and crossbones
GHS06

Avvertenze

Danger

Indicazioni di pericolo

H301,H315,H319,H335

Classi di pericolo

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 9

1 of 9

Sulfasalazine 97.0-101.5%

Sigma-Aldrich

S0883

Sulfasalazine

Sulfasalazine British Pharmacopoeia (BP) Reference Standard

BP779

Sulfasalazine

Sulindac ≥98.0%

Sigma-Aldrich

S8139

Sulindac

L-Dihydroorotic acid ≥99%

Sigma-Aldrich

D7128

L-Dihydroorotic acid

Decylubiquinone ≥97% (HPLC)

Sigma-Aldrich

D7911

Decylubiquinone

Mdivi-1 ≥98% (HPLC), powder

Sigma-Aldrich

M0199

Mdivi-1

Uridine powder, BioReagent, suitable for cell culture

Sigma-Aldrich

U3003

Uridine

Metotrexato powder, BioReagent, suitable for cell culture, ≥98% (HPLC)

Sigma-Aldrich

M8407

Metotrexato

Uridine ≥99%

Sigma-Aldrich

U3750

Uridine

J M Kremer et al.
Clinical and experimental rheumatology, 22(5 Suppl 35), S95-100 (2004-11-24)
Leflunomide was first shown to have disease-modifying properties in a rat model of adjuvant-induced arthritis. Leflunomide has been subsequently used with success in several animal models of tissue and organ allograft and of autoimmune disease including collagen- and adjuvant-induced arthritis
K F Siemasko et al.
Transplantation, 61(4), 635-642 (1996-02-27)
Leflunomide is an immunosuppressive drug capable of inhibiting cellular and humoral mediated responses in vivo. The mechanism responsible for suppression of B cell antibody responses in vivo has not been identified. In this study we demonstrate that leflunomide functions to
X Xu et al.
Biochemical pharmacology, 52(4), 527-534 (1996-08-23)
Previous studies have demonstrated that the active metabolite of leflunomide, A77 1726 [N-(4-trifluoromethylphenyl-2-cyano-3-hydroxycrotoamide)], is capable of inhibiting the activities of tyrosine kinases and dihydroorotate dehydrogenase (DHO-DHase). In the present study, we define the relative contribution of these activities to the
T R Brazelton et al.
Current opinion in immunology, 8(5), 710-720 (1996-10-01)
Among all the new immunosuppressive molecules being investigated either preclinically or clinically, four stand out: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide (and its malononitriloamide analogs). Each drug has distinct mechanisms of immunosuppressive action, and in the past year
Nicolae Leca
Current opinion in organ transplantation, 14(4), 370-374 (2009-06-11)
Leflunomide has been used off-label in renal transplantation because of the attractive combination of antiviral and immunosuppressive effects. This study intends to review the clinical applications of leflunomide with interest to transplantation. In renal transplantation, particularly in BK nephropathy, the
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.